According to the latest report by IMARC Group, titled “Dry Eye Syndrome Market Report by Disease Type (Evaporative Dry Eye Syndrome, Aqueous Dry Eye Syndrome), Drug Type (Anti-inflammatory Drugs, Lubricant Eye Drops, Autologous Serum Eye Drops), Product (Liquid Drops, Gel, Liquid Wipes, Eye Ointment, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2024-2032,” the global dry eye syndrome market size reached US$ 4.8 Billion in 2023. Dry Eye Syndrome is a common eye condition characterized by inadequate lubrication and moisture on the surface of the eye. It occurs when the tear glands fail to produce enough tears or when the tears evaporate too quickly, resulting in dryness, irritation, and discomfort. It includes symptoms such as a gritty or sandy sensation in the eyes, redness, stinging or burning sensations, excessive tearing, blurred vision, and sensitivity to light. There are several underlying causes of dry eye syndrome, including aging, hormonal changes, certain medications, medical conditions such as autoimmune disorders, environmental factors, and lifestyle choices. Some commonly used treatments include the use of artificial tears or lubricating eye drops to provide temporary relief.
Global Dry Eye Syndrome Market Trends:
Lifestyle changes and increased screen time is driving the global market. Moreover, with the widespread use of digital devices such as smartphones, tablets, and computers, individuals are exposed to prolonged periods of screen viewing, leading to decreased blink rates and increased evaporation of tears. This prolonged visual tasking and reduced blinking contribute to the development of dry eye symptoms, thereby fueling the demand for DES treatments. Besides, with the global population aging, the prevalence of DES is expected to increase, leading to a greater demand for effective treatments and management options. Furthermore, various environmental factors, such as pollution and dry climates, are augmenting the DES market as exposure to environmental pollutants, allergens, and irritants can trigger or exacerbate dry eye symptoms, thus catalyzing the market. Additionally, living in regions with dry climates or spending time in air-conditioned or heated environments can lead to increased evaporation of tears and worsened DES symptoms. Along with this, continual advancements in diagnostic technologies and techniques have improved the accuracy and efficiency of DES diagnosis, allowing for earlier detection and intervention. This is creating a positive market outlook. Looking forward, the market value is projected to reach US$ 7.5 Billion by 2032, expanding at a CAGR of 5% during 2024-2032.
Market Summary:
- Based on the disease type, the market has been segmented into evaporative and aqueous dry eye syndromes. Currently, evaporative dry eye syndrome represents the largest market segment.
- On the basis of the drug type, the market has been divided into anti-inflammatory drugs, lubricant eye drops, and autologous serum eye drops. Among these, anti-inflammatory drugs exhibit a clear dominance in the market.
- Based on the product, the market has been bifurcated into liquid drops, gel, liquid wipes, eye ointment, and others. Among these, liquid eye drops account for the largest market share.
- On the basis of the distribution channel, the market has been divided into hospital, retail and online pharmacies. Among these hospital pharmacies exhibits a clear dominance in the market.
- Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. Among these, North America holds the leading position in the market.
- The competitive landscape of the market has also been examined, with some of the key players Akorn Operating Company LLC, Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb Incorporated, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., and Santen Pharmaceutical Co. Ltd.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Disease Type, Drug Type, Product, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered |
Akorn Operating Company LLC, Alimera Science, Allergan plc., Auven Therapeutics, Bausch + Lomb Incorporated, GlaxoSmithKline plc, Nicox S.A., Novartis AG, Otsuka Holdings Co. Ltd., and Santen Pharmaceutical Co. Ltd. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800